<b>Supplementary Table</b><b>. Detailed Demographic and Clinical Characteristics of the Patients with Juvenile Localized Scleroderma</b>

Plus signs (+) indicate positivity; “Negative” indicates negative results for ANA, RF, and the extended myositis/scleroderma panel.Abbreviations: F, female; M, male; y, years; m, months; mo, months; wk, weeks; Teli, telitacicept; ANA, antinuclear antibody; RF, rheumatoid factor; Anti-β2GP1, anti-beta-2 glycoprotein 1; Anti-PM-Scl, anti-polymyositis/scleroderma; MTX, methotrexate; Pred, prednisone.* Disease duration refers to the time from disease onset to the initiation of telitacicept.† Initial mLoSSI/LoSDI represent the clinical activity and damage scores assessed prior to the initiation of any first-line systemic therapy (MTX with or without Prednisone).‡ Concomitant therapy refers to background medications maintained during telitacicept treatment. Standard dosages used in this study: MTX, 10-15 mg/m² once weekly (oral); Prednisone, 1 mg/kg/day (oral).§ Prednisone taper duration indicates the time taken to successfully discontinue oral corticosteroids after starting telitacicept.“—” indicates no prednisone was used during the study period; “Still on” indicates the patient is currently tapering.